TY - JOUR
T1 - Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease
AU - Sundararajan, Miel
AU - Rathinam, Sivakumar R.
AU - Thundikandy, Radhika
AU - Kanakath, Anuradha
AU - Balamurugan, S.
AU - Vedhanayaki, R.
AU - Miller, D. Claire
AU - Lim, Lyndell L.
AU - Suhler, Eric B.
AU - Al-Dhibi, Hassan A.
AU - Arellanes-Garcia, Lourdes
AU - Reddy, Amit K.
AU - Feng, Shu
AU - Doan, Thuy
AU - Porco, Travis C.
AU - Shantha, Jessica G.
AU - Acharya, Nisha R.
AU - Gonzales, John A.
N1 - Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2025
Y1 - 2025
N2 - Purpose: The choroidal thickening and serous retinal detachments that characterize Vogt-Koyanagi-Harada (VKH) disease can be imaged in detail using spectral domain optical coherence tomography (SD-OCT). Whether specific qualitative and quantitative SD-OCT features at presentation were associated with visual outcomes in a randomized controlled trial comparing methotrexate to mycophenolate for steroid-sparing control of uveitis were evaluated. Methods: An exploratory subanalysis of data from the FAST trial in which SD-OCT images from VKH participants were analyzed for presence/absence of bacillary detachments, retinal pigment epithelium (RPE) folds, and internal limiting membrane (ILM) fluctuations was performed. A modified RPE undulation index was calculated to provide a quantifiable surrogate marker for choroidal folds. Results: SD-OCT images were available from 158 eyes with VKH. At baseline, bacillary detachments were present in 23.5% of eyes, RPE folds in 22.8% of eyes, and ILM fluctuations in 35.2% of eyes. For each 0.1 unit increase in modified RPE undulation index, there was an associated 0.13 increase in mean logMAR BSCVA at baseline. None of the SD-OCT features were associated with BSCVA at the 6-month primary endpoint. Indeed, mean final BSCVA was similar in those with and without the SD-OCT features of interest at baseline, and was between 0.1 and 0.2 logMAR (Snellen visual acuity 20/25 to 20/30). Conclusions: While eyes with VKH may present with a variety of SD-OCT imaging pathology prior to starting immunosuppression with methotrexate or mycophenolate mofetil, final visual outcome in our study was excellent. With appropriate immunosuppression, good visual outcomes are possible in VKH. ClinicalTrials.gov Identifier NCT01829295 Date of Registration: April 11, 2013.
AB - Purpose: The choroidal thickening and serous retinal detachments that characterize Vogt-Koyanagi-Harada (VKH) disease can be imaged in detail using spectral domain optical coherence tomography (SD-OCT). Whether specific qualitative and quantitative SD-OCT features at presentation were associated with visual outcomes in a randomized controlled trial comparing methotrexate to mycophenolate for steroid-sparing control of uveitis were evaluated. Methods: An exploratory subanalysis of data from the FAST trial in which SD-OCT images from VKH participants were analyzed for presence/absence of bacillary detachments, retinal pigment epithelium (RPE) folds, and internal limiting membrane (ILM) fluctuations was performed. A modified RPE undulation index was calculated to provide a quantifiable surrogate marker for choroidal folds. Results: SD-OCT images were available from 158 eyes with VKH. At baseline, bacillary detachments were present in 23.5% of eyes, RPE folds in 22.8% of eyes, and ILM fluctuations in 35.2% of eyes. For each 0.1 unit increase in modified RPE undulation index, there was an associated 0.13 increase in mean logMAR BSCVA at baseline. None of the SD-OCT features were associated with BSCVA at the 6-month primary endpoint. Indeed, mean final BSCVA was similar in those with and without the SD-OCT features of interest at baseline, and was between 0.1 and 0.2 logMAR (Snellen visual acuity 20/25 to 20/30). Conclusions: While eyes with VKH may present with a variety of SD-OCT imaging pathology prior to starting immunosuppression with methotrexate or mycophenolate mofetil, final visual outcome in our study was excellent. With appropriate immunosuppression, good visual outcomes are possible in VKH. ClinicalTrials.gov Identifier NCT01829295 Date of Registration: April 11, 2013.
KW - Retinal pigment epithelium undulation index
KW - SD-OCT
KW - Vogt-Koyanagi-Harada
UR - http://www.scopus.com/inward/record.url?scp=85202527279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202527279&partnerID=8YFLogxK
U2 - 10.1080/09273948.2024.2391420
DO - 10.1080/09273948.2024.2391420
M3 - Article
C2 - 39190826
AN - SCOPUS:85202527279
SN - 0927-3948
VL - 33
SP - 263
EP - 270
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 2
ER -